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Abstract
Introduction Adverse drug reactions (ADRs) are associated with signiicant health-related and inancial burden, and multiple 
sources are currently utilized to actively discover them. Social media has been proposed as a potential resource for monitor-
ing ADRs, but drug-speciic analytical studies comparing social media with other sources are scarce.
Objectives Our objective was to develop methods to compare ADRs mentioned in social media with those in traditional 
sources: the US FDA Adverse Event Reporting System (FAERS), drug information databases (DIDs), and systematic reviews.
Methods A total of 10,188 tweets mentioning adalimumab collected between June 2014 and August 2016 were included. 
ADRs in the corpus were extracted semi-automatically and manually mapped to standardized concepts in the Uniied Medi-
cal Language System. ADRs were grouped into 16 biologic categories for comparisons. Frequencies, relative frequencies, 
disproportionality analyses, and rank ordering were used as metrics.
Results There was moderate agreement between ADRs in social media and traditional sources. “Local and injection site 
reactions” was the top ADR in Twitter, DIDs, and systematic reviews by frequency, ranked frequency, and index ranking. 
The next highest ADR in Twitter—fatigue—ranked ifth and seventh in FAERS and DIDs.
Conclusion Social media posts often express mild and symptomatic ADRs, but rates are measured diferently in scientiic 
sources. ADRs in FAERS are reported as absolute numbers, in DIDs as percentages, and in systematic reviews as percent-
ages, risk ratios, or other metrics, which makes comparisons challenging; however, overlap is substantial. Social media 
analysis facilitates open-ended investigation of patient perspectives and may reveal concepts (e.g. anxiety) not available in 
traditional sources.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-018-0707-6) contains 
supplementary material, which is available to authorized users.
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Key Points 
Social media are a robust source of health-related data 
and may serve as complementary sources of adverse 
drug reaction (ADR) information from the patient per-
spective.
Analyses of social media posts allow for open, scientiic 
investigation of ADRs that may be either not reported 
or underreported in spontaneous reporting systems and 
primary literature, thus contributing to a more complete 
safety proile.
Challenges prevent current natural language process-
ing methods to automatically map all consumer ADR 
expressions to standard forms. Improvements to auto-
matic text processing approaches should make the meth-
ods presented here scalable by reducing the annotation 
burden.
1 Introduction
Adverse drug reactions (ADRs) are a signiicant cause of 
morbidity and mortality worldwide, are responsible for 
approximately 5.3% of hospital admissions, and are esti-
mated to rank between fourth and sixth in cause of mortal-
ity in the USA, making them crucial in healthcare decision 
making [1–4]. Recent studies have highlighted ADRs as 
costly and their discovery a public health priority [4–6]. The 
seriousness of the problem has led to investigations of novel 
methods to discover and assess ADR information from dis-
tinct sources [7–10]. The World Health Organization (WHO) 
deines an ADR as “a response to a drug which is noxious 
and unintended, and which occurs at doses normally used 
in man for the prophylaxis, diagnosis, or therapy of disease, 
or for the modiications of physiological function” [4]. The 
importance of ADRs should not be understated given that 
many drugs may result in harm and, when diferent options 
are available, avoidance of ADRs may be a deciding factor in 
formulary inclusion or treatment choice. There may also be 
narrow beneit-versus-harm trade-ofs. A number of eforts 
originating from diferent parts of the globe attempt to sys-
tematically identify and report ADRs. However, comprehen-
sive detection and reporting of ADRs remains incomplete [2, 
4, 11]. Each reporting source has limitations. In particular, 
underreporting is apparent in traditional pharmacovigilance 
data, clinical trials, and other types of studies [12]. Drug 
information databases (DIDs), which are compilations of 
information primarily used by medical professionals, are 
limited by timeliness of updates from primary literature 
and package insert data. In recent years, social media have 
emerged as promising sources of timely data that are cur-
rently underused and could help supplement data from other 
sources [13, 14]. Little is known about the similarities and 
diferences between ADRs obtained from social media and 
traditional sources.
The primary objective of this study was to explore meth-
ods to elucidate the similarities and diferences between data 
extracted from social media and other ADR reporting sys-
tems in an attempt to create a complete ADR proile for a 
single medication. We selected adalimumab as the focus of 
this study because it is approved for chronic diseases with 
signiicant health burdens, has been a top-selling drug in the 
USA for many years, and has both common and rare adverse 
events [15–18]. Adalimumab is a biologic, a class of medica-
tions that are large molecules manufactured in living cells 
for the treatment of diseases. It is a monoclonal antibody 
that binds to tumor necrosis factors, ultimately resulting in 
decreased inlammatory activity in immune-based condi-
tions. Its primary use is in immune-based arthritis, Crohn’s 
disease, ulcerative colitis, and psoriatic arthritis, although 
additional indications have been approved by the US FDA. 
Adalimumab has many common side efects such as injec-
tion site reactions, and, rarely, it increases the risk of serious 
infections [17]. We hypothesized that social media provide 
information to support what is known about medications, 
along with additional information that is not available from 
traditional systems.
1.1  Challenges with Adverse Drug Reaction (ADR) 
Reporting
Precise ADR reporting rates are unknown but estimated at 
approximately 10–20% [12, 19, 20]. Data collection and 
reporting varies in diferent settings. For example, ADRs 
measured in a hospital setting have been estimated at 86%, 
whereas the rate in outpatient settings may be 16–48% 
[21–25]. Further diferences may be seen in both observa-
tional and experimental studies, all of which sufer from 
underreporting [12]. Problems arise with diferences in 
reporting rates, imprecise evaluation and estimation of 
ADRs, and a scarcity of recent studies to describe ADR 
rates [3, 26–29]. The following subsections detail some of 
these limitations.
1.1.1  ADRs Reported in Primary Literature
DIDs and systematic reviews rely on primary literature, such 
as reports of randomized controlled trials (RCTs). In gen-
eral, RCTs are designed and powered to explore eicacy and 
often are neither large enough nor have suicient follow-up 
to identify rare, long-term ADRs or ADRs that occur after 
the drug has been discontinued. RCT data may be limited if 
trials exclude speciic patient populations such as children, 
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elderly, pregnant women, patients with multiple diseases, 
and those with potential drug interactions. Aggregating data 
from RCTs is another method to examine the association 
between medications and ADRs. Systematic reviews aim 
to identify, evaluate, and summarize indings of relevant 
studies, mostly RCTs. When appropriately conducted, they 
provide reliable estimates about the efects (beneicial and 
adverse) of interventions.
Detection of ADRs through observational studies can be 
problematic because they are typically not designed with 
ADR detection as the primary outcome. Pharmacoepidemio-
logic (PE) studies measure the efects and ADRs of drugs 
in large populations. PE studies may use secondary data 
sources such as administrative health claims databases [30]. 
Health claims are a robust source of real-world data, yet the 
databases were not designed to detect ADRs. These obser-
vational studies may be valuable for hypotheses generation, 
education applications, and even pharmacovigilance, yet it 
is diicult to establish cause and efect relationships, the 
opportunity for bias is great, and they rank low in evidence-
based medicine. More common are case series and case 
reports, which rely on researchers or motivated clinicians to 
investigate, evaluate, and report the case(s) [31].
1.1.2  ADRs and Spontaneous Reporting Systems
The FDA Adverse Event Reporting System (FAERS) is a 
spontaneous reporting mechanism in the USA that has man-
datory and voluntary components. FAERS may be one of the 
most eicient current methods to capture rare events that are 
associated with drug use [32]. FDA requires manufactur-
ers to report serious ADRs within 15 days of receipt. ADR 
reports are maintained in the FAERS database, and manu-
facturers are estimated to provide 80% of pharmaceutical 
reports [33]. Reporting by consumers and healthcare profes-
sionals accounts for the remaining reports, and the level of 
detail and content in each of these reports may limit their 
usefulness. Healthcare professional and consumer reporting 
is voluntary, leading to both bias in what is reported and 
underreporting. Healthcare professionals may be unsure of 
who is responsible for submitting an ADR report (20–36%) 
[11]. Further obstacles to healthcare professionals report-
ing are insuicient time to report and unclear reporting pro-
cesses; they may also be unsure of the speciic drug causing 
the reaction.
Other organizations maintain ADR reporting databases, 
for example, the Institute for Safe Medication Practices, but 
its focus is safe use and error prevention [34]. The Agency 
for Healthcare Research and Quality supports research to 
evaluate ADRs but does not compile them in a database 
[35]. The American Society of Health System Pharmacists 
has a recommended plan for reporting ADRs, but the focus 
is primarily hospital based [36]. The WHO and European 
countries have spontaneous surveillance mechanisms, such 
as the UK Medicines and Healthcare Products Regulatory 
Agency’s Yellow Card program, the European Medicines 
Agency’s EudraVigilance, and the WHO Uppsala Monitor-
ing Center in Sweden, all of which have similar reporting 
challenges.
1.1.3  ADRs Reported in Social Media
Social media platforms have been explored in the recent past 
as a potential resource for pharmacovigilance [13]. Given 
the limitations of spontaneous reporting systems (SRS) and 
other sources, social media in general and Twitter specii-
cally was identiied as a source to quantify adverse events 
[13, 14, 37]. Social media has the potential to inform and 
augment adverse event reporting systems and self-reported 
perception of health that may not have been previously col-
lected from other sources. Patient reporting brings novel 
information, more detail, and information on severity and 
impact of ADRs in daily life [38]. Furthermore, ADRs asso-
ciated with over-the-counter medications may not be cap-
tured in either hospital or ambulatory settings but appear in 
social media.
In prior research, we developed natural language process-
ing (NLP) methods that address speciic challenges of min-
ing health-related information from social media texts [13, 
39, 40]. The properties of social media texts that pose NLP 
challenges include misspellings, data imbalance, non-stand-
ard expressions, and noise, to name a few. For social media-
based pharmacovigilance, we completed large-scale eforts 
of manual annotation and used them to develop supervised 
classiication methods to ilter out noise [41] and informa-
tion extraction methods to extract standard and non-standard 
mentions of ADRs [39]. These advances mainly allow the 
reduction of the volume of data that needs to be manually 
annotated, given that any study on speciic ADRs or their 
frequencies to estimate incidence or detect a signal [such 
as proportional reporting ratio (PRR)] requires mapping 
of the extracted mentions to standard ADR nomenclature 
[such as the Uniied Medical Language System (UMLS) 
or MedDRA], a task commonly known as normalization. 
This remains an unresolved challenge, with lexicon-based 
approaches (e.g. MetaMap) performing very unreliably 
[42, 43] and missing all but the almost exact mentions of 
the ADRs. Effective automatic normalization methods 
will potentially enable large-scale comparisons of many 
drug–ADR pairs from social media to other sources. When 
this study was conducted, because an efective normalization 
approach was lacking, we chose to use automatic methods 
for ADR extraction only, followed by manual mapping of 
the mentions to standard nomenclature. Manual normaliza-
tion of all posts reporting an ADR removed the potential 
bias of only using posts that could be mapped automatically. 
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We compared ADRs from Twitter to known sources such as 
DIDs, systematic reviews, and FAERS to determine simi-
larities and diferences. This information may relect patient 
perceptions or indicate signals of medication-related prob-
lems. The annotation efort plus the three-way comparison 
of social media data to other sources forced us to limit the 
study to the ADRs associated with a single drug. While this 
manual efort was cumbersome, it was necessary to ensure 
accurate comparisons, and it lays down the framework for 
future larger-scale comparisons of multiple drugs and ADRs 
from diferent sources. We hypothesize that social media 
provide not only information about medication use that sup-
ports what is known about medications but also useful infor-
mation that is not available from traditional adverse event 
reporting systems.
2  Methods
Twitter posts were collected from June 2014 to August 
2016 via the public application programming interface 
(API) (https ://dev.twitt er.com/strea ming/publi c) using the 
keywords Humira and adalimumab and their automatically 
generated misspellings [40]. Tweets were processed by 
ADRMine [39], which is a sequence-labeling system relying 
on conditional random ields, to extract ADRs. All extracted 
ADRs were manually annotated as perceived ADRs or some 
other categories. In addition, to assess what the automatic 
system could be missing, a random sample of 1000 tweets 
were selected from those not identiied by ADRMine and 
similarly annotated. All manual annotations were performed 
following the guidelines described by O’Connor et al. [44]. 
Identiied ADRs were mapped to UMLS [45] concept IDs.
Twitter adalimumab ADRs were aggregated into broad 
categories of biologic systems to facilitate comparison 
between the diferent ADR sources. For example, local injec-
tion site reactions are known and common for adalimumab 
and may be identiied with the UMLS concept “injection 
site burning” or “injection site bleeding” or “bruising,” and 
others. FAERS reports these local reactions as “injection site 
pain” or “injection site hemorrhage” and others, whereas 
DIDs report the reactions in one subcategory of local injec-
tion site ADRs. For this study, these local dermatologic reac-
tions were combined into one category, and a similar process 
was used to create each biologic system category.
We conducted disproportionality analyses by computing 
PRRs, which is a measure of disproportionality in signal 
detection [46, 47]. This measure has been used for SRS, and 
the score was customized to suit social media data [48]. The 
goal of disproportionality analysis is to detect drug–ADR 
pairs that are reported more frequently than other pairs of 
concepts. Relatively small numbers of reports may lead to 
identiiable signals. Table 1 presents the contingency matrix 
for the disproportionality measure, which is given by the 
following equation:
2.1  Comparison of Tweets and Known Sources 
of ADR Reporting
We compared ADR categories mentioned in tweets with 
three known sources of ADR reporting: FAERS, DIDs, and 
systematic reviews of adalimumab.
2.1.1  Comparison Metrics: Frequency, Ranking, Relative 
Frequency of ADRs
Frequencies were compared and ranked as the absolute per-
centages identiied across sources. To compare the relative 
magnitude of diferences between the ADR categories, we 
computed the relative frequencies of the most mentioned 
categories of ADRs. “Pain” was deined as the index com-
parator with a value of 1.0 because it was reported similarly 
across Twitter, FAERS, and the DIDs. To obtain a relative 
frequency of an ADR compared with pain, the percentage 
reporting that ADR was divided by the percentage report-
ing pain. For example, 17.2% of tweets mentioned muscu-
loskeletal complaints, and 10% of tweets mentioned pain. 
The relative frequency of musculoskeletal mentions would 
be 1.7% in FAERS.
2.1.2  US Food and Drug Administration Adverse Drug 
Event System
We obtained a report of ADRs for adalimumab using 
Opened API (ResearchAE.com) from 1 June 2014 through 
August 2016. ADR categories were compared between 
tweets and FAERS reports by frequency, rank order, rela-
tive frequencies, and PRR metrics.
2.1.3  Drug Information Databases
We compared the frequency of ADR tweets with simi-
lar events mentioned in the three major DIDs utilized by 
PRR =
A∕(A + B)
C∕(C + D)
.
Table 1  Disproportionality two-by-two contingency matrix
ADR adverse drug reaction
User posts with the sus-
pected ADR
User posts 
without the 
ADR
User posts mentioning 
adalimumab
A B
All other posts C D
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healthcare professionals—Micromedex®,  Lexicomp®, and 
Clinical  Pharmacology®—using a composite frequency 
[see Electronic Supplementary Material (ESM) 1]. These 
databases are common sources of drug information for clini-
cians and use multiple sources, including primary literature, 
to present evidence-based eicacy and adverse event data. 
ADR categories were compared between tweets and DIDs by 
frequency, rank order, relative frequencies, and PRR metrics.
2.1.4  Systematic Reviews of Adalimumab
We conducted an overview of systematic reviews of adali-
mumab to identify ADRs and compared the ADRs identiied 
in systematic reviews of adalimumab with the frequencies 
of the ADRs in the tweets. Systematic reviews are consid-
ered the gold standard in evidence-based medicine. They 
are often used as the basis of clinical guidelines and are 
considered as guidance in evidence-based policy decisions. 
To identify ADRs associated with adalimumab in system-
atic reviews, a range of databases including Epistimonikos 
(https ://www.epist emoni kos.org/) and the DARE archive 
(https ://www.crd.york.ac.uk/CRDWe b/Resul tsPag e.asp) 
were searched in February 2017 for synonyms of the terms 
Humira and adalimumab. No date or language restrictions 
were applied to the searches. Systematic reviews were 
included if Humira was one of the primary interventions 
and investigators had searched for and presented usable data 
related to the ADRs of this intervention.
Comparing data collected from social media with outputs 
from systematic reviews was challenging. We undertook a 
two-step approach where we irst presented indings and 
categories of ADRs identiied via Twitter and systematic 
reviews. The second step involved analyses to examine the 
strength of the relationship between adverse events and 
adalimumab—a rank order of the ADR frequencies. This 
gave an indication of agreement between the most frequently 
occurring ADRs from each source. These approaches used 
the data or statistics as presented by the systematic review 
authors, which in most instances meant we limited our com-
parison to the absolute numbers from the active arm only. 
However, this was more comparable to the data collected 
from tweets, where a control arm was not available.
3  Results
A total of 10,188 tweets were collected and 2617 potential 
ADRs identiied automatically by ADRMine. ADRMine 
obtained an F-measure of 0.58 (recall 0.91, precision 0.43) 
over the dataset. The high recall obtained by the system 
suggests that most true ADR expressions were captured 
by the system. Manual review of these and an additional 
1000 tweets randomly chosen from those not identiied by 
ADRMine resulted in 801 true ADRs, which were mapped 
to 232 unique UMLS concept IDs. Among others, 112 were 
ambiguous because it was unclear whether they were ADRs, 
259 were ambiguous because the mention may have referred 
to either the indication for the drug or the ADR, 250 referred 
to the indication for adalimumab, 98 referred to an ADR 
or indication for another drug, six referred to a beneicial 
efect of the drug, 32 were duplicates, and 1162 mentioned 
the drug but not an ADR or indication for the drug or other 
classiiable mention. These tweets were excluded from the 
analysis. Table 2 presents sample Twitter posts and type 
categorization.
3.1  Classiication of Tweets into Categories Based 
on UMLS Concept IDs
After excluding tweets that did not mention an ADR, 
extracted UMLS concept names describing similar adverse 
events were combined into one biologic category, where 
possible, to measure the frequency of a broad concept as 
previously described. For example, UMLS concept names, 
including “knee pain,” “muscles pain”, and multiple other 
“pain” mentions were grouped into one general “pain” cat-
egory. Other categories created by pooling related concepts 
included “abdominal issues”, “allergic reactions”, “anxiety 
and mood mentions”, “dizziness and neurologic symptoms”, 
“fatigue symptoms”, “headaches”, “infections”, “cardiac 
symptoms”, and “sick mentions”. Finally, serious illnesses 
such as “Guillain Barre”, “myocardial infarction”, and “fatal 
outcome” were noted. Table 3 presents the top 16 aggregated 
categories mentioned in adalimumab tweets, along with the 
DID and FAERS report frequencies, frequency ranks, and 
relative index values.
3.2  Comparison of ADRs in Tweets with FAERS 
and Drug Information Databases
Absolute frequency ranking and relative ranking with index 
values are presented in Table 3. Local “injection site reac-
tions”, “fatigue”, and “pain” accounted for the majority of 
concept categories for Twitter mentions at 187 (23.7%), 136 
(17.2%), and 79 (10.0%), respectively; this was similar to 
FAERS reports, at 24.4, 11.4, and 11.6%, respectively. While 
these ADRs were frequently reported in the drug informa-
tion databases, the top three events were “injection site reac-
tions”, “skin/dermatologic reactions”, and “headache”. PRR 
scores for the term “pain” were high at 16.4 when the scores 
for the speciic mentions (e.g. muscle pain and chest pain) 
were combined. The PRR score most applicable to “injection 
site pain” was “welts”, which also had a high score, of 8.4.
The relative trend of the top ADRs in Twitter of “injection 
site pain”, “musculoskeletal fatigue”, “gastrointestinal com-
plaints”, and “neurologic complaints”, including “anxiety”, 
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“depression”, and “mood” are similar, as illustrated in Fig. 1. 
Not all relative reports were similar. FAERS reported derma-
tologic ADRs three times more frequently than pain (index 
value 3.3), whereas Twitter reports of dermatologic ADRs 
were 0.5 times that of pain. The DID reports of dermato-
logic ADRs were more similar to those in FAERS than on 
Twitter, with an index value of 2.2. The ive ADR catego-
ries with notable disparity between the three sources were 
“dermatologic”, “hypersensitivity”, “headache”, “infection”, 
and “joint and bone” ADRs. Of those categories, “dermato-
logic”, “hypersensitivity”, and “bone and joint ADRs” had 
the highest index values when compared with pain in the 
Table 3  Adverse event categories mentioned in adalimumab tweets
CNS central nervous system, FAERS US FDA Adverse Event Reporting System
a Pain referent
Twitter FAERS Drug Information Databases
Adverse Event Category n Percent Frequency 
Rank
Index 
 valuea
n Percent Frequency
Rank
Index 
 Valuea
Percent Frequency 
Rank
Index 
 Valuea
Local: Injection Site 187 23.70 1 2.4 603 24.36 2 2.1 13.80 1 2.5
Musculoskeletal: Fatigue/ Weakness/ 
Spasms/ Malaise
136 17.24 2 1.7 282 11.39 7 1.0 7.00 5 1.3
Pain,all 79 10.01 3 1.0 288 11.64 5 1.0 5.50 7 1.0
Gastrointestinal 48 6.08 4 0.6 288 11.64 5 1.0 7.00 5 1.3
Neurologic: Anxiety/ Depression/ 
Insomnia/ Panic/ Mood
43 5.45 5 0.5 113 4.57 12 0.4 2.50 10 0.5
Dermatologic 41 5.20 6 0.5 950 38.38 1 3.3 12.00 2 2.2
Neurologic: Headache 30 3.80 7 0.4 109 4.40 13 0.1 12.00 2 2.2
Infection 30 3.80 7 0.4 427 17.25 3 0.4 9.60 4 1.7
Hypersensitivity 30 3.80 7 0.4 33 1.33 16 1.5 1.00 15 0.2
Neurologic: CNS Dizzy-fall/ Gait/ 
Groggy/ Memory/ Confusion
21 2.66 10 0.3 154 6.22 9 0.5 2.50 10 0.5
Endocrine/ Metabolic 16 2.03 11 0.2 56 2.26 14 0.2 4.50 8 0.8
Musculoskeletal: Arthralgia/ Joint/
Bone complaints
15 1.90 12 0.2 360 14.55 4 1.3 3.00 9 0.5
Cardiovascular 14 1.77 13 0.2 175 7.07 8 0.6 2.50 10 0.5
Hepatic 7 0.89 14 0.1 54 2.18 15 0.2 2.40 14 0.4
Hematology/ Oncology 7 0.89 14 0.1 118 4.77 10 0.4 1.00 15 0.2
Table 2  Examples of tweets expressing adverse drug reactions, indications, beneicial efects, and other information. Uniied medical language 
system concept codes are shown in the irst column
ADR adverse drug reaction, UMLS uniied medical language system
UMLS 
concept 
code
Comment type Comment
Pain ADR Humira is the worst pain I have ever felt—and I’ve felt some pretty bad pain in life
Pain Unsure @username can’t sleep in pain, reminds me of your super woman strength to cope with it! How did ur irst 
Humira injection go babe?
Pain Indication or ADR I just gave myself my irst Humira injection. Ouch! Any suggestions on reducing the pain and making it more 
tolerable?
Pain Other drug I had terrible joint pain with Remicade. I switched to Humira and have had no major side efects
Pain Beneicial I’d like to add, Humira is kicking RA’s ass! I’ve got energy! Pain & swelling down a lot! Haven’t taken ibu-
profen in 2 days either :)
Fatigue ADR Humira made me perpetually fatigued and sick
Fatigue Unsure One of those days—wicked tired and I have to get going to make it to physical therapy today. Two days after 
each Humira shot is sucky
Fatigue Other drug I think I am still trying to get over the tiredness from Ibiza and Humira is due
Fatigue Beneicial I could swear that Humira is giving me so much energy
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FAERS reports (3.3, 1.5, 1.3, respectively). “Hypersensi-
tivity”, “infection”, and “headache” ADRs had the highest 
index value relative to “pain” in the drug information data-
bases (2.2, 2.2, and 1.7, respectively). The relative ranking 
of index values for Twitter were less than the other data 
sources in “gastrointestinal”, “joint and bone”, “cardiovas-
cular”, “hepatic”, “hematology and oncology”, and “respira-
tory” categories (Fig. 1).
3.3  ADRs Identiied Through Systematic Reviews
Database searches identiied 38 systematic reviews evalu-
ating adalimumab. After assessment of each paper, we 
included 20 systematic reviews (see ESM 2). Seven reviews 
were excluded because they did not evaluate any adverse 
efects [49–55], three were excluded because they pooled 
serious ADRs or all ADRs without naming or quantify-
ing the adverse efects [56–59], and another was excluded 
because it evaluated pharmacoeconomic studies [60]. Five 
systematic reviews contained data on combination ther-
apy rather than adalimumab monotherapy or compared 
adalimumab therapy with another therapy [61–65]. One 
review [66] contained only two RCTs, both of which were 
already included in another review [67] with the same 
data extracted and was therefore excluded. If a study was 
included in more than one review, we checked to see whether 
diferent outcomes were measured and removed duplicates. 
No further systematic reviews were excluded on this basis. 
In total, 20 systematic reviews remained for inclusion to 
examine ADRs to adalimumab (Appendix 2 in the Supple-
mentary material). One included study [15] appeared to have 
been updated [68], but the included studies were not listed. 
In this instance, we extracted data from both papers but did 
not include both sets of data in our results.
Adalimumab was evaluated for different indications, 
study designs, and results measures in the 20 included sys-
tematic reviews. Indications included rheumatoid arthritis, 
inlammatory arthritis, ankylosing spondylitis, psoriasis, 
ulcerative colitis, inlammatory bowel disease, or Crohn’s 
disease. While half of the reviews were limited to RCTs only 
[67, 69–77], eight included RCTs and other study designs 
(such as case series or non-randomized trials) [15, 68, 
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78–83], and two included case reports, case series, cohort 
studies, or uncontrolled trials, not RCTs [84, 85]. Results 
from the reviews were either reported as rates of adverse 
efects (nine reviews) [67, 70, 71, 73, 76, 79, 80, 83, 84], 
events per patient-years (six reviews) [15, 68, 69, 72, 85, 
86], risk ratios (one review) [77], or were simply listed with 
little or no numerical data (four reviews) [75, 78, 81, 82].
We were only able to obtain the rank order of adverse 
efects from ten systematic reviews [67, 68, 70, 73, 74, 76, 
77, 80, 83, 84]. Two of the nine systematic reviews report-
ing rates of ADRs [71, 79] and three of the six systematic 
reviews reporting events per patient-years [15, 72, 85] did 
not provide numerical data for all the adverse efects listed, 
and one systematic review only evaluated one ADR (cancer) 
[69]. For the systematic reviews that did not provide ade-
quate numerical data, we only compared whether particular 
ADRs were mentioned [15, 71, 72, 75, 77–79, 81, 82, 85].
3.3.1  Comparison of Mentioned and Ranked ADRs
Within the ten systematic reviews for which we were able 
to rank order ADRs, the two categories from the top 16 cat-
egories in Twitter not covered in these systematic reviews 
were “neurologic: anxiety/depression/insomnia/panic/mood” 
and “endocrine/metabolic”, which were the 5th and 11th 
top adverse efects on Twitter, respectively. To compare the 
ranking of ADR categories in systematic reviews to Twitter, 
we irst compared the overall results from the ten reviews 
with rank order data and then carried out a more detailed 
analysis with the included RCTs from these reviews that 
reported rates in the treatment and placebo arms. No single 
adverse event category was included in all ten systematic 
reviews; however, “infection” ranked seventh on Twitter, 
was covered in nine systematic reviews, and ranked irst 
overall in the systematic reviews. “Injection site reactions” 
(top ADR on Twitter) and “hematology/oncology” (14th on 
Twitter) were listed in six reviews. “Injection site reactions” 
were ranked second overall, and “hematology/oncology” 
was ranked ifth overall in the systematic reviews. Interest-
ingly “infection” and “hematology/oncology” were much 
more prominent ADRs in the systematic reviews than in 
social media. Conversely, “musculoskeletal: fatigue” (third 
on Twitter) and “pain” (fourth on Twitter) were much more 
prominent in social media than in systematic reviews (men-
tioned in one and four reviews, respectively). Some ADRs 
reported in the systematic reviews were not in the top 16 
categories from Twitter. Most notable were serious ADRs 
such as “death”—although this was not common.
Figure 2 displays the results of a more detailed analy-
sis using rates of ADRs reported in the systematic reviews 
[70, 73, 76, 83]. This igure was produced by summing the 
adverse events from the RCTs in each category to calculate 
the absolute percentage diference for adalimumab versus 
placebo, and it displays the rank order of attributable fre-
quency, which is the intervention ADR rate minus the con-
trol event rate. Only “infection” had complete data in all 11 
RCTs and “injection site” was reported in nine RCTs. One 
major issue was that “pain” was not reported as an ADR 
in any of the trials, primarily because pain is non-speciic 
and could be applicable to any biologic system or the dis-
ease. Figure 2 highlights that the investigators may only be 
interested in measuring infections and local reactions, while 
important ADRs remain poorly ascertained.
4  Discussion
This study illustrates the similarities and diferences in 
ADRs discovered for adalimumab from diferent sources 
and highlights the diiculties of comparing or combining 
data from the diferent sources because each has a unique 
set of limitations. FAERS is a voluntary reporting system 
and, while the total number of ADRs reported is known, 
the total number of individuals exposed to the drug are not. 
Fig. 2  Change in risk for 
adverse drug reactions in those 
receiving adalimumab versus 
placebo in randomized con-
trolled trials
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Thus, incidence cannot be determined from FAERS data. 
Incidence may be measured in clinical studies, which are 
the primary source of information for drug information data-
bases and systematic reviews. However, these studies may of 
short duration and have limited patient populations, and they 
are normally designed to detect eicacy. Most systematic 
reviews are also not designed with ADRs as the primary out-
come; in many cases, the individual studies that contribute 
to the reviews report ADRs by percentage, incidence rates 
utilizing person time, or other crude measures. Given the 
limitations of these sources, it is reasonable to utilize social 
media as additional sources of patient-reported ADRs. We 
sought to verify the extent to which social media encapsu-
lated knowledge regarding ADRs identiied in traditional 
sources and to determine what additional information about 
ADRs social media data may provide us.
4.1  Comparison with Related Work
Social media are a recognized source of ADR information 
within the research community, yet methods of extract-
ing, analyzing, and interpreting it are many, as are the pro-
posed uses [8, 13, 14, 26, 87–90]. Furthermore, automated 
approaches relying on social media show varying perfor-
mances, and continued developments to improve precision 
are needed. Sarker et al. [13] conducted a review of studies 
that described automatic data mining approaches for ADR 
detection. They identiied 22 studies that used health-related 
and general social media sites as the source for mining. The 
authors concluded that while health-related sources con-
tained more speciic ADR data, publicly annotated data 
to allow for further development of methods to identify 
ADR–drug pairs were lacking. Lardon et al. [87] conducted 
a review of ADR extraction from social media to determine 
what methods had been used to identify post-marketing 
pharmacovigilance data and evaluate the signals contained 
in user postings. The authors identiied studies that focused 
on extraction and evaluation of ADR–drug pairs and found 
that four compared the data with those in FAERS, seven 
studies used experts to evaluate ADR comments, and none 
compared frequency and relative ranking of comments with 
multiple sources of pharmacovigilance data. We found that, 
when comparing ADRs in Twitter with those in FAERS, 
more common ADRs had similar relative values across 
sources, and likewise for the less common ADRs. Twitter 
ADRs that occurred at a moderate frequency were relatively 
underreported when compared with those in FAERS. For 
example, “dermatologic” ADRs had a relative value of 0.5 
in Twitter and 3.3 in FAERS or 2.2 in the drug information 
databases (Fig. 1). “Hypersensitivity” was reported more 
frequently in the DIDs (index 2.2) and relatively less in 
Twitter and FAERS (0.4 and 0.1, respectively).
Our study utilized multiple sources, whereas a previous 
comparison only examined systematic reviews and social 
media [14]. Only 12 of the 51 identiied studies used medical 
dictionaries in their search strategy to identify ADRs. There 
was general agreement between the extraction source and 
existing ADR data: over 80% of the ADRs found in Twitter 
were supported by the indings from other sources. Milder 
ADRs were reported at a higher frequency in social media. 
By comparison, we found that when evaluating the relative 
ranking of the ADR categories, the most frequently and 
infrequently experienced ADRs were similar across sources, 
with the exception of “dermatologic” ADRs reported in 
FAERS. The moderately reported ADRs were more likely to 
difer between Twitter, FAERS, and DIDs. Our inding that 
dermatologic ADRs were more often reported in FAERS is 
similar to previous indings that some social media ADRs 
are underrepresented compared with in pharmacovigilance 
systems [14]. The relative ranking of lesser-reported ADRs 
was similar across the sources. For example, cardiovascular, 
hepatic, and respiratory ADRs had relatively low reports in 
all the sources (Fig. 1).
A study similar to ours attempted to compare ADRs 
across sources (not social media) using an index value for 
relative comparisons from WHO reports, published case 
reports, and results of their meta-analysis [10]. The authors 
selected ADRs associated with amiodarone, a medication 
with known pulmonary, thyroid, and rare ophthalmic com-
plications. There was little agreement within the sources for 
the top ADR, as cardiac problems were ranked highest in the 
authors’ meta-analysis but lowest in WHO and case reports. 
Thyroid problems were reported in the top three of each data 
source, indicating some level of agreement. Additionally, 
ophthalmic ADRs were reported to be rare, resulting in the 
low ranking in each of the sources. Our study, unlike that of 
Loke et al. [10], included social media as a source, and we 
found that the moderately reported ADRs varied in relative 
reporting frequency (dermatologic, hypersensitivity, head-
ache, and infection).
One method employed to examine the potential of social 
media as an early warning system identiied safety sig-
nals reported to the FDA then retrospectively determined 
whether the signals were present in Twitter and Facebook 
[91]. The authors selected ten drug-event pairs from FAERS 
then examined user posts to determine whether the event 
was mentioned before the FAERS signal. Their semi-auto-
mated analysis identiied 13 posts in which the drug may 
have caused the event in question—six were identiied as 
deinitely causal, probable, or possible (46%). While they 
sought to determine whether the known drug–event pair 
signals were present in social media before FAERS report-
ing, our study examined the complete stream of postings 
coming anew for a speciic drug without the advantage of 
hindsight. With the state of current automatic NLP methods, 
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it is relatively easier to look for single, expected efects than 
to ind and analyze all mentions of any type of efect.
These studies underscore the challenges in comparing 
ADRs between sources. ADRs may be reported as a per-
centage of occurrence in exposed individuals in scientiic 
literature, but diiculties arise because social media studies 
do not have a control treatment. Absolute measures of fre-
quency may be the most straightforward comparison, but if a 
study reports a low incidence (e.g. 3 per 1000 patient-years), 
comparisons are diicult to describe. Relative measures are 
especially challenging, depending upon the comparator and 
control group. Control groups may difer between trials, so 
the relative efect also difers. Further complicating compari-
sons is concomitant therapy (e.g. adalimumab plus metho-
trexate). Methotrexate may be adjusted or dose titrated in a 
trial, so the adalimumab-treated patients may be receiving a 
diferent dose of the concomitant medication. This is prob-
lematic when ADRs are related to dose response.
DIDs compile ADRs from multiple sources, including 
scientiic literature, and are therefore subject to the same 
frequency challenges. The FAERS database of post-market-
ing ADRs is subject to additional challenges because it can 
only report absolute occurrence numbers. Even with multi-
ple reporting systems, ADRs are underreported, and social 
media appear to be sources to augment existing reporting of 
ADRs and health perceptions [87, 92, 93].
In addition to issues with comparing ADRs with diferent 
measures, DIDs categorize and display ADRs diferently, 
which may lead to interpretation diferences. Micromedex 
lists ADRs in the “Quick Answers” section as either com-
mon or serious. Categories within this section include ana-
tomical systems arranged by frequency of occurrence. For 
example, “dermatologic” includes injection site reaction of 
5–20%, depending on the age category of the user. The “In 
Depth Answers” section lists eight subcategories within the 
dermatologic section. Lexicomp presents adverse reactions 
by frequency in a similar fashion to Micromedex, with three 
categories of severity (< 1%, 1–10%, > 10%). An anatomical 
system may appear in each of these categories. It is diicult 
to know precisely what to expect in terms of ADRs or how 
to compare them with other sources.
When compared with Twitter, systematic reviews have 
the advantage of including studies that have a control group. 
However, many of the adverse events listed in the treatment 
arm have similar frequencies in the control or placebo arm. 
Computation of an odds ratio for the ADRs could solve the 
diiculty in determining diferences, but this is typically 
not feasible as most studies are only powered to detect dif-
ferences in the primary outcome. We used the raw data in 
the treatment group because this is more easily comparable 
with the data collected from social media. Some systematic 
reviews simply listed ADRs that occurred in the included 
studies with no frequencies or gave frequencies for selected 
ADRs only. The majority of systematic reviews focused 
on clinical efectiveness. Outcomes in systematic reviews 
should be pre-speciied at the protocol stage, at which time 
the ADRs may be unknown. These factors may explain some 
of the poor reporting of the ADR outcomes and may give 
an impression that there are no signiicant diferences in 
adverse events. The various indications and range of study 
designs included in the systematic reviews meant that a plot 
of relative ADR frequencies from the systematic reviews 
would be likely to produce a large scatter because they were 
all so diferent. This confounds our subsequent comparison 
with other sources. Therefore, we could not produce a single 
consistent estimate from all the relevant systematic reviews 
that could be used to compare against Twitter or the DIDs, 
or FAERS data. Hence, we produced a rank order from only 
a small proportion of the systematic reviews available.
A strength of our study is that we identiied ADRs that 
may not be known, were not reported to the FDA, or were 
not well described elsewhere. For example, UMLS con-
cepts in tweets that were not mentioned in the DIDs were 
“sleep” and “nervous”. “Sleep” tweets included both ends 
of the spectrum, such as “day one on the new Humira and 
I sleep the entire morning away”, and “this Humira keeps 
me either awake or it only lets me sleep for 2 h”. In gen-
eral, however, Twitter users appeared to associate lack of 
sleep with the drug, whereas the majority of tweets con-
taining the ADR “nervousness/anxiety” referred not to how 
the drug made them feel but to the anxiety caused by the 
act of self-injecting. For example, “still get nervous when 
injecting sometimes” or “always get nervous giving myself 
a Humira shot”. These tweets occur at a diferent frequency 
than ADRs reported to the FDA, presumably because they 
are not directly a cause of the drug but are related to patient 
feelings about the drug. These two examples support our 
hypothesis that ADRs and patient perspectives (known or 
unknown) are available in social media. The unknown con-
cepts here may relect a true ADR or the subjective percep-
tions or sentiments associated with the drug but, in either 
case, require further study.
Current ADR identiication eforts have beneits and chal-
lenges. Challenges in interpreting tweets include the limited 
length and the relection of patients’ perceptions of a condi-
tion or drug when the condition may or may not be associ-
ated with the drug at all. Furthermore, the data mined may 
have privacy concerns. Additional limitations include the 
reliability of tweets, but the semi-automatic process does 
provide a mechanism for excluding unrelated comments 
while capturing user perceptions. Scalability may be con-
sidered as limiting because the combined automated pro-
cess of extracting tweets and subsequently compiling the 
DID reporting and conducting the systematic review took 
an enormous amount of work. However, limitations of auto-
matic approaches may be alleviated as further advances are 
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made in NLP methods applied to social media. Ongoing 
advances in NLP and normalization techniques will allow 
this type of comparison to be completed for multiple drugs. 
Studies such as ours motivate and give signiicance to those 
eforts.
5  Conclusion
Twitter is a robust source of health-related data, and there-
fore it is important to continue to reine methods to best uti-
lize it. We conducted a prodigious comparison of tweets to 
known sources of ADR information and determined the level 
of agreement. Generally, concepts were in moderate agree-
ment with known ADRs, and concepts were found in Twit-
ter that were not in DIDs (e.g. nervous/sleep). This study 
demonstrates that it is possible and worthy to harvest and 
compare ADRs found in social media with those from typi-
cal sources to augment what is known, while a large-scale 
efort (that includes multiple medications) is still diicult 
given the level of efort required. Challenges to analyzing 
social media may be attenuated as further advances are made 
to automatic NLP methods.
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